Interview: UCB Sees Bimekizumab As Good Long-Term Bet

UCB immunology chief Emmanuel Caeymaex tells Scrip that despite intense competition, the dual neutralization approach of bimekizumab in inhibiting both interleukin-17A and IL-17F could result in a treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis that may produce faster and more durable clinical improvements than the drugs already on the market.

Tortoise
Slow and steady may win the race

UCB Group's bimekizumab may be well behind the competition in the crowded fields of psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS) but to paraphrase Bob Dylan, the slow one now may later be fast if the Belgian drug maker's product candidate continues to hit the high endpoints the company has been setting in clinical studies.

The latest set of strong data on the monoclonal antibody which inhibits both interleukin-17A and IL-17F were presented at the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category